Table 1 Baseline patient characteristics
Total (n = 314) | Good responders (n = 92) | Poor responders (n = 222) | P-value | |
|---|---|---|---|---|
Age, years, mean ± SD | 59.1 ± 10.1 | 59.2 ± 10.1 | 59.1 ± 10.1 | 0.953 |
Sex, Female | 145 (46.2) | 53 (57.6) | 92 (41.4) | 0.009 |
History of smoking (n = 303) | 303 | 86 | 217 | 0.015 |
Current smoker | 68 (22.4) | 12 (14.0) | 56 (25.8) | |
Ex-smoker | 76 (25.1) | 18 (20.9) | 58 (26.7) | |
Never smoker | 159 (52.5) | 56 (65.1) | 103 (47.5) | |
Stage | 0.456 | |||
≤IIIB | 19 (6.1) | 7 (7.6) | 12 (5.4) | |
IV | 295 (93.9) | 85 (92.4) | 210 (94.6) | |
Stage M1a | 93 (29.6) | 44 (47.8) | 49 (22.1) | <0.001 |
Stage M1b | 202 (64.3) | 41 (44.6) | 161 (72.5) | <0.001 |
Type of chemotherapy | 0.002 | |||
Pemetrexed monotherapy | 263 (83.8) | 68 (73.9) | 195 (87.8) | |
Pemetrexed combination | 51 (16.2) | 24 (26.1) | 27 (12.2) | 0.552 |
Platinum | 34 (10.8) | 15 (16.3) | 19 (8.6) | |
Non-platinum | 17 (5.4) | 9 (9.8) | 8 (3.6) | |
Previous chemotherapy | 0.068 | |||
0 | 44 (14.0) | 18 (19.6) | 26 (11.7) | |
≥1 | 270 (86.0) | 74 (80.4) | 196 (88.3) | |
Previous regimen (n = 270)a | 270 | 74 | 196 | |
Response to Gemcitabineb | 88/175 (50.3) | 32/49 (65.3) | 56/126 (44.4) | 0.013 |
Response to EGFR-TKI | 79/128 (61.7) | 16/34 (47.1) | 63/94 (67.0) | 0.040 |
Response to Paclitaxel | 36/56 (64.3) | 5/14 (35.7) | 31/42 (73.8) | 0.010 |
Response to Docetaxel | 7/14 (50.0) | 4/6 (66.7) | 3/8 (37.5) | 0.592 |
Response to Miscellaneous | 7/15 (46.7) | 3/4 (75.0) | 4/11 (36.4) | 0.282 |